RT Journal Article
T1 The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.
A1 Hardy, Timothy
A1 Wonders, Kristy
A1 Younes, Ramy
A1 Aithal, Guruprasad P
A1 Aller, Rocio
A1 Allison, Michael
A1 Bedossa, Pierre
A1 Betsou, Fay
A1 Boursier, Jerome
A1 Brosnan, M Julia
A1 Burt, Alastair
A1 Cobbold, Jeremy
A1 Cortez-Pinto, Helena
A1 Day, Chris P
A1 Dufour, Jean-Francois
A1 Ekstedt, Mattias
A1 Francque, Sven
A1 Harrison, Stephen
A1 Miele, Luca
A1 Nasr, Patrik
A1 Papatheodoridis, George
A1 Petta, Salvatore
A1 Tiniakos, Dina
A1 Torstenson, Richard
A1 Valenti, Luca
A1 Holleboom, Adriaan G
A1 Yki-Jarvinen, Hannele
A1 Geier, Andreas
A1 Romero-Gomez, Manuel
A1 Ratziu, Vlad
A1 Bugianesi, Elisabetta
A1 Schattenberg, Jörn M
A1 Anstee, Quentin M
A1 LITMUS Consortium, 
K1 Biomarker
K1 Cirrhosis
K1 NAFLD
K1 NASH
AB Non-Alcoholic Fatty Liver Disease (NAFLD), a progressive liver disease that is closely associated with obesity, type 2 diabetes, hypertension and dyslipidaemia, represents an increasing global public health challenge. There is significant variability in the disease course: the majority exhibit only fat accumulation in the liver but a significant minority develop a necroinflammatory form of the disease (non-alcoholic steatohepatitis, NASH) that may progress to cirrhosis and hepatocellular carcinoma. At present our understanding of pathogenesis, disease natural history and long-term outcomes remain incomplete. There is a need for large, well characterised patient cohorts that may be used to address these knowledge gaps and to support the development of better biomarkers and novel therapies. The European NAFLD Registry is an international, prospectively recruited observational cohort study that aims to establish a large, highly-phenotyped patient cohort and linked bioresource. Here we describe the infrastructure, data management and monitoring plans, and the standard operating procedures implemented to ensure the timely and systematic collection of high-quality data and samples. Already recruiting subjects at secondary/tertiary care centres across Europe, the Registry is supporting the European Union IMI2-funded LITMUS 'Liver Investigation: Testing Marker Utility in Steatohepatitis' consortium, which is a major international effort to robustly validate biomarkers that diagnose, risk stratify and/or monitor NAFLD progression and liver fibrosis stage. The European NAFLD Registry has the demonstrable capacity to support research and biomarker development at scale and pace.
YR 2020
FD 2020-10-09
LK http://hdl.handle.net/10668/16403
UL http://hdl.handle.net/10668/16403
LA en
DS RISalud
RD Apr 4, 2025